SPYRE THERAPEUTICS INC.

NASDAQ: SYRE (Spyre Therapeutics, Inc.)

Last update: 05 Jul, 11:43AM

15.76

0.26 (1.68%)

Previous Close 15.50
Open 15.53
Volume 506,667
Avg. Volume (3M) 616,350
Market Cap 951,172,736
Price / Sales 650.22
Price / Book 2.86
52 Weeks Range
10.91 (-30%) — 40.26 (155%)
Earnings Date 5 Aug 2025 - 11 Aug 2025
Diluted EPS (TTM) -3.06
Total Debt/Equity (MRQ) 0.06%
Current Ratio (MRQ) 8.06
Operating Cash Flow (TTM) -169.86 M
Levered Free Cash Flow (TTM) -68.57 M
Return on Assets (TTM) -25.34%
Return on Equity (TTM) -65.82%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Spyre Therapeutics, Inc. Bearish Bullish

AIStockmoo Score

0.1
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 2.5
Technical Oscillators -4.0
Average 0.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SYRE 951 M - - 2.86
CGON 2 B - - 2.81
CVAC 1 B - 5.81 1.62
REPL 861 M - - 1.74
VIR 781 M - - 0.750
ZVRA 616 M - - 12.54

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 8.71%
% Held by Institutions 106.07%

No data within this time range.

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria